Financial Performance - The company's revenue for Q1 2025 was ¥800,275,782.51, a decrease of 7.06% compared to ¥861,092,255.54 in the same period last year[5] - Net profit attributable to shareholders was ¥189,135,410.14, down 13.37% from ¥218,334,248.48 year-on-year[5] - Basic earnings per share decreased by 20.41% to ¥0.39 from ¥0.49 in the same period last year[5] - Total operating revenue for the current period was ¥800,275,782.51, a decrease of 7.06% from ¥861,092,255.54 in the previous period[18] - Net profit for the current period was ¥190,072,222.04, a decline of 13.75% compared to ¥220,443,620.50 from the previous period[19] - Earnings per share (EPS) for the current period was ¥0.39, down from ¥0.49 in the previous period[20] Cash Flow - The net cash flow from operating activities was -¥148,787,719.58, a significant decline of 231.41% compared to ¥113,224,704.67 in the previous year[5] - Cash inflow from operating activities totaled ¥557,099,837.33, a decrease of 25.06% from ¥743,368,930.59 in the previous period[22] - The net cash flow from operating activities was -$148.79 million, a decrease from $113.22 million in the previous period[23] - The cash outflow for operating activities totaled $705.89 million, compared to $630.14 million previously[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,182,545,912.53, reflecting a slight increase of 0.39% from ¥7,154,652,043.13 at the end of the previous year[5] - Current assets totaled CNY 3,824,674,042.04, up from CNY 3,785,861,965.80 at the start of the period[14] - Total current liabilities decreased to CNY 661,546,113.92 from CNY 821,464,141.00, indicating a reduction of approximately 19.5%[15] - The company’s total liabilities decreased to CNY 1,239,504,273.17 from CNY 1,392,436,610.63, indicating a reduction of approximately 11%[15] - Total liabilities amounted to ¥1,342,322,632.33, a decrease from ¥1,504,364,037.54[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,296[11] - The company’s equity position remains strong, with significant holdings by major shareholders, including Li Wenmei at 20.32% and Wang Jihua at 10.30%[13] - Total equity attributable to shareholders of the parent company increased to ¥5,743,386,505.55 from ¥5,554,388,042.84[16] Changes in Financial Metrics - The weighted average return on equity was 3.35%, down from 4.50% in the previous year[5] - The company reported a significant increase in accounts receivable by 89.06%, reaching ¥27,575,749.01 due to increased sales revenue settled by notes[9] - The company experienced a 62.99% decrease in cash and cash equivalents, totaling ¥306,674,463.35, primarily due to investments in financial products[9] - The company recorded a 1217.59% increase in fair value gains, amounting to ¥11,431,121.13, attributed to the fair value changes of trading financial assets[9] Inventory and Other Assets - Inventory decreased to CNY 319,592,386.44 from CNY 359,555,274.55, representing a decline of about 11.1%[14] - The company’s non-current assets totaled CNY 3,357,871,870.49, down from CNY 3,368,790,077.33[15] Accounting and Audit - The company did not undergo an audit for the first quarter report[24] - The new accounting standards will be implemented starting in 2025, affecting the financial statements[24]

海外业务收入高速增长，商业化进展成绩亮眼 2024 年，公司海外实现收入11.03 亿元，同比增长43.23%。（1）慢病管理检测：海外收入实现同比快 速增长。公司持续深化"一带一路"沿线发展中国家的市场深耕，在中小型医疗机构领域形成差异化竞争 优势，扩大终端市场份额。（2）传染病检测：在发展中国家，公司聚焦传染病检测公卫市场，深化与 政府及国际卫生组织的合作，扩大在血源性传染病等领域的市场份额。在美国，呼吸道检测业务取得了 突破性进展，公司的新型冠状病毒、甲型流感病毒及乙型流感病毒三联检测试剂盒（POC 版）/三联家 庭检测试剂盒（OTC 版）产品获得美国FDA EUA 授权，并于2025年1 月获得美国FDA 510（k）许可。 此外，公司的新冠抗原检测产品（OTC版）于2024 年9 月获得美国FDA 510（k）许可。 事件：近日，公司发布2024 年年报：2024 年实现营业收入30.65 亿元，同比上涨10.85%，主要系国际 业务增长带动；归母净利润5.62 亿元，同比上涨15.18%；扣非归母净利润4.97 亿元，同比上涨 19.90%。 其中，2024 年第四季度营业收入8.83 亿元，同比 ...

Core Viewpoint - The Shenzhen Stock Exchange held its first collective performance briefing for listed companies in 2024, focusing on the theme "New Growth for Enterprises: Private Enterprises Competing in the Middle Stream," showcasing the latest developments of private enterprises and addressing investor concerns regarding technological innovation, tariff challenges, internationalization, and development strategies [1]. Group 1: Technological Innovation - Innovation is identified as the core driving force for the development of the private economy, with Shenzhen's private listed companies making significant investments in R&D, technology innovation, and patent accumulation [3]. - Jianfan Bio focuses on the R&D, production, and sales of biomedical materials and high-tech medical devices, particularly excelling in blood purification technology, and plans to enhance production management and diversify its product line [3]. - ZhiJian Electronics, a leader in consumer lithium-ion batteries, is committed to a forward-looking R&D strategy and aims to enhance its core competitive advantages while exploring market growth opportunities [3]. - Wanfu Bio sees digital pathology as a significant transformation opportunity and is developing comprehensive digital pathology solutions to reduce doctors' workloads [4]. - Xinlitai is exploring AI applications in drug discovery and clinical research to improve innovation efficiency and plans to deepen AI's role in drug design and data mining [4]. Group 2: Tariff Challenges - Companies are closely monitoring international trade policies and are implementing measures such as increasing domestic sales and developing new overseas markets to mitigate the impact of high tariffs imposed by the U.S. [6]. - Zongshen Power reported that its domestic sales accounted for 51.99% of total revenue in 2024, slightly higher than export business, and has taken proactive measures to address tariff risks [6]. - Yunjigroup highlighted that its supply chain has a high localization rate, effectively mitigating tariff fluctuations, and is capitalizing on new overseas projects due to the ongoing high prosperity cycle in the mining industry [7]. - Jianfan Bio is expanding into new markets while increasing its overseas business share, particularly in heavy liver disease and critical illness applications [7]. - Wanfu Bio has over 20 years of experience in international markets and continues to innovate to maintain growth in its international business despite tariff challenges [7]. Group 3: Development Trends - Shenzhen's private listed companies demonstrate resilience and vitality, with a significant number of companies contributing to economic development and technological innovation [9]. - As of March 2025, there are 2,181 private listed companies in Shenzhen, accounting for 76% of the total, with a combined market value of 22.65 trillion yuan, representing 69% of the total market value [9]. - In 2023, 582 private enterprises disclosed their annual reports, achieving a total revenue of 6.25 trillion yuan, a year-on-year increase of 6.62%, and a net profit of 419.9 billion yuan, a growth of approximately 1% [9]. - Jianfan Bio is investing in high-value resin and medical device projects, aiming to enhance market share and secure product supply [10]. - Xinlitai is transitioning from generic to innovative drugs, with increasing revenue contributions from new patented products [11].

债券代码：123064 债券简称：万孚转债 证券代码：300482 证券简称：万孚生物 广州万孚生物技术股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他： | | 参与单位名称及 | 深圳证券交易所及线上、线下参会的投资者 | | 人员姓名 | | | 时间 | 2025 年 4 月 18 日 | | 地点 | 深圳证券交易所 8 楼上市大厅 | | 上市公司接待人 | 董事长：王继华 | | 员姓名 | 董事会秘书：胡洪 | | | 一、公司基本情况及 2024 年全年经营情况介绍 | | | 公司 1992 年成立，深耕体外诊断领域 30 余年，提供快速诊断试剂及配 | | | 套仪器的研发、生产制造、营销及服务，致力于提升优质医疗的可及性、便捷 | | | 性和可负担性。目前公司依托九大技术平台形成了心脑血管疾病、炎症、肿瘤、 | | | 传染病、毒检、优生优育等检验领域丰富的产品线，拥有广州、杭州、香港、 | | ...

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2025-021 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于万孚转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 转股价格：人民币 27.00 元/股 转股时间：2021 年 3 月 8 日至 2026 年 8 月 31 日 根据《广州万孚生物技术股份有限公司向不特定对象发行可转换公司债券募 集说明书》（以下简称"《募集说明书》"）中相关约定：在本次发行的可转换公司 债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收 盘价低于当期转股价格的 80%时，公司董事会有权提出转股价格向下修正方案并 提交公司股东大会表决。上述方案须经出席会议的股东所持表决权的三分之二以 上通过方可实施。 广州万孚生物技术股份有限公司（以下简称"公司"）股票自 2025 年 4 月 7 ...

广州万孚生物技术股份有限公司 关于公司开展外汇套期保值业务的可行性分析报告 鉴于外汇套期保值业务与公司的经营密切相关，公司董事会授权董事长及 其授权代表依据公司制度的规定具体实施外汇套期保值业务方案，签署相关协 议及文件。授权期限自董事会审议通过之日起 12 个月内有效，上述额度在期限 内可循环滚动使用。 一、公司开展外汇套期保值业务的目的 为有效防范公司及全资、控股子公司（以下简称"子公司"）开展境外业 务等所产生外币收付汇结算等过程中外币汇率大幅波动的风险，提高外汇资金 使用效率，公司及子公司拟与有关政府部门批准、具有相关业务经营资质的金 融机构开展外汇套期保值业务。公司开展的外汇套期保值业务与生产经营紧密 相关，能进一步提高应对外汇波动风险的能力，更好地规避和防范外汇汇率波 动风险，增强财务稳健性。 二、外汇套期保值业务的基本情况 （一）主要涉及币种及业务品种 公司及子公司拟开展的外汇套期保值业务只限于从事与公司实际经营业务 所使用的主要结算货币相同的币种，主要外币币种为美元。 公司拟开展的外汇套期保值业务主要为远期结售汇业务。 （二）业务规模及投入资金来源 根据实际需求情况，公司及子公司本次批准发生的 ...

证券代码：300482 证券简称：万孚生物 公告编号：2025-020 广州万孚生物技术股份有限公司 关于参加深圳证券交易所"成长新启航·民企百舸竞中 流" 2024 年度集体业绩说明会的公告 一、本次业绩说明会的安排 1、召开时间：2025 年 4 月 18 日（星期五）15:00－17:00 2、召开地点：深圳证券交易所 8 楼上市大厅 3、召开方式：视频直播与图文转播 4、公司出席人员：公司董事长王继华女士，董事会秘书胡洪女士。 二、投资者问题征集方式 为充分尊重投资者、提升交流的针对性，现就本次业绩说明会提前向投资者 公开征集问题，广泛听取投资者的意见和建议。投资者可提前登陆深交所"互动 易"平台（http://irm.cninfo.com.cn）"云访谈"栏目进入本次业绩说明会页面，或扫 描二维码（附后）进入问题征集专题页面进行提问。公司将在本次业绩说明会上 对投资者普遍关注的问题进行回答。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）将于 2025 年 4 月 18 日（星期五）15:00－17: ...

证券代码：300482 证券简称：万孚生物 债券代码：123064 债券简称：万孚转债 广州万孚生物技术股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访□业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他：电话会议，投资者线上交流会 | | 参与单位名称及 | 华泰证券股份有限公司、中信建投证券股份有限公司、中信证券股份有限公 | | 人员姓名 | 司、国盛证券股份有限公司、信达证券股份有限公司、中国银河证券股份有 | | | 限公司、天风证券股份有限公司、太平洋证券股份有限公司、开源证券股份 | | | 有限公司、西南证券股份有限公司、国信证券股份有限公司、国联民生证券 | | | 股份有限公司、国泰海通证券股份有限公司、华创证券有限责任公司、中邮 | | | 证券有限责任公司、中泰证券股份有限公司、兴业证券股份有限公司等机构 | | 时间 | 2025 年 4 月 10 日 | | 地点 | 电话会议 | | 上市公司接待人 | 董事长：王继华 | | 员姓名 | 董事 ...

Core Viewpoint - Wanfu Biotech has achieved initial success in its operational breakthrough, with significant revenue and profit growth in 2024, driven by favorable industry conditions and continuous product innovation [1][2]. Financial Performance - In 2024, the company reported total revenue of 3.065 billion yuan, a year-on-year increase of 10.85%, and a net profit of 562 million yuan, up 15.18% [2]. - The company's non-recurring net profit reached 497 million yuan, reflecting a growth of 19.9% [2]. - Total assets at the end of 2024 amounted to 7.155 billion yuan, increasing by 23.96%, while net assets grew by 22.99% to 5.554 billion yuan [2]. Business Segments - The chronic disease management testing segment showed the strongest performance, generating revenue of 1.369 billion yuan, a growth of 22.38% [1][2]. - Other business segments also experienced growth: infectious disease testing revenue was 1.042 billion yuan (up 9.50%), prenatal testing revenue was 294 million yuan (up 9.97%), and drug abuse testing revenue was 286 million yuan [2]. - International revenue reached 1.103 billion yuan, a significant increase of 43.23%, accounting for 55.42% of total revenue [2]. R&D Investment - Wanfu Biotech has invested heavily in R&D, with cumulative R&D expenditure reaching 2.346 billion yuan from 2019 to 2024 [3][4]. - In 2024, R&D investment was 438 million yuan, representing 14.30% of total revenue [4]. - The company holds a total of 642 product registration certificates, with 344 in China and 298 overseas, including 74 from the US FDA and 207 from the EU CE [3]. Innovation and Technology - The company has established multiple technology platforms, including immunochromatography, immunofluorescence, and molecular diagnostics, contributing to a diverse product line [3]. - In 2024, Wanfu Biotech obtained 55 new patents, including 39 invention patents, enhancing its competitive edge [4]. - The company employs over 700 R&D personnel and maintains a leading position in R&D intensity and team strength within the industry [4].

Summary of Wanfu Biological Conference Call Company Overview - **Company**: Wanfu Biological - **Fiscal Year**: 2024 - **Revenue**: 3.065 billion CNY, up 10.85% YoY - **Net Profit**: 562 million CNY, up 15.18% YoY - **Key Business Segments**: - Infectious Disease Testing: 1.042 billion CNY, up 9.5% YoY - Chronic Disease Management: 1.369 billion CNY, up 22.38% YoY - Prenatal and Neonatal Testing: 294 million CNY, up 9.97% YoY - Drug Abuse Testing: 286 million CNY Core Insights and Arguments - **Market Positioning**: - Increased market share in domestic influenza testing and strategic breakthroughs in respiratory testing in the U.S. [2][3] - Focus on industrial markets for infectious disease testing internationally [4] - **R&D Investment**: - R&D expenditure reached approximately 440 million CNY, accounting for 14% of revenue, with 82 new products launched [2][8] - New product categories include high-speed testing equipment and upgraded chemiluminescence and fluorescence platforms [2][8] - **International Expansion**: - Rapid growth in overseas revenue, with the international department growing approximately 30% YoY [2][9] - Differentiated competitive advantages established in Belt and Road countries, targeting medium-sized third-party laboratories and emergency departments [2][9] - **Product Development**: - Investment in AI-assisted diagnostic software for cervical cancer, achieving the first Class III medical device registration in China [2][11][15] - Development of a digital pathology model integrating AI, enhancing diagnostic efficiency [11][16] Additional Important Points - **Gross Margin Improvement**: - Gross margin increased by about 1 percentage point in 2024 due to improved product line margins and cost control measures [5][17] - **Response to Tariffs**: - Company has implemented strategies to mitigate the impact of U.S. tariffs, including local production and inventory management [5][14] - The U.S. market accounts for approximately 10% of total business, with manageable tariff impacts [14] - **Future Growth Projections**: - Focus on key product lines such as respiratory disease testing and blood-borne infectious disease detection for 2025 [19] - Plans to enhance hospital efficiency with more instruments and launch upgraded fluorescence platforms [19][20] - **Local Production Initiatives**: - Successful establishment of local production facilities in Uganda, with plans for further localization in other countries [20][21] - **Regulatory Adaptation**: - Quick adjustments to pricing strategies in response to regulatory changes in the domestic market, leading to increased sales [21] - **Market Strategy**: - Emphasis on academic marketing and distributor engagement to drive market expansion in 2025 [22] - **Product Line Expansion**: - Introduction of new products in drug testing and respiratory markets, with ongoing negotiations for partnerships in the U.S. [24][25] - **Sales Channels**: - Significant contributions from online sales platforms, with a focus on maintaining customer base and market share in the U.S. [25][26] This summary encapsulates the key points from the conference call, highlighting Wanfu Biological's performance, strategic initiatives, and future outlook in the healthcare diagnostics industry.